Detalhe da pesquisa
1.
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
Mol Pharmacol
; 92(6): 694-706, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28974538
2.
RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Biochem Biophys Res Commun
; 477(1): 62-67, 2016 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27282480
3.
Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.
Bioorg Med Chem Lett
; 25(14): 2818-23, 2015 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26022843
4.
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
Clin Cancer Res
; 26(20): 5338-5347, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32694156
5.
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.
Atherosclerosis
; 247: 48-57, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26868508
6.
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.
Data Brief
; 8: 1280-8, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27570805
7.
Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48-57].
Atherosclerosis
; 253: 345, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27211480
8.
Purification and characterization of recombinant Streptomyces griseus aminopeptidase.
Protein Expr Purif
; 30(1): 62-8, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12821322